Close this search box.

Markison to succeed Heino as Lantheus CEO

ARTICLE | Management Tracks

Plus: Lisa Olson becomes CEO of Enthera, and updates from Bayer, Neumora, PDS and more

By Richard Guy, Biopharma Analyst, and Gunjan Ohri, Data Content Analyst

January 24, 2024 12:14 AM UTC

Brian Markison will succeed Mary Anne Heino as CEO of  Lantheus Holdings Inc. (NASDAQ:LNTH). Markison, who is the radiopharmaceutical company’s chairman, will serve as executive chair until March 1, when he becomes CEO and Heino becomes chair. Markison was CEO and director of RVL Pharmaceuticals plc (NASDAQ:RVLP), and has served as a board member of Lantheus for the past 11 years. Julie McHugh, a board member, was named lead independent director.

Lisa Olson became CEO of Enthera s.r.l., an inflammatory disease company targeting insulin growth factor binding protein family. Olson was CSO and head of research at Magenta Therapeutics Inc., and held several roles at AbbVie Inc. (NYSE:ABBV) and Abbott Laboratories (NYSE:ABT). Enthera also announced that it has initiated enrollment of a Phase Ib trial of Ent001 to treat ulcerative colitis following positive top-line safety results in Phase Ia. …